​Goutham’s career in gene therapy is defined by the seamless integration of scientific excellence and industrial execution. With over 15 years of expertise in genome engineering and preclinical viral vector manufacturing, he has advanced into leadership roles driving upstream process optimization and scalable viral vector manufacturing. ​

​Goutham joined DINAMIQS as Head of Upstream Development in 2021. Across both academic and industry settings, he has led multidisciplinary teams in advancing viral vector technologies for CNS, Cardiac and muscular gene therapy applications. ​

​He holds a PhD in Biochemistry from the University of Göttingen, Germany.